Skip to search formSkip to main contentSkip to account menu

endralazine

National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2004
2004
SummaryFive and 10 mg single oral doses of a new vasodilator antihypertensive, endralazine (E) were given on separate occasions… 
2004
2004
SummaryA sensitive HPLC assay has been used to determine the effect of food on plasma endralazine levels in 8 patients with… 
2004
2004
SummaryNineteen out-patients with moderate to severe essential hypertension were treated daily for 3 years, with an average dose… 
1983
1983
The direct-acting vasodilator, endralazine, in combination with a beta-adrenoceptor blocker significantly reduced the blood… 
1983
1983
Endralazine (BQ 22–708, Miretilan) and guanfacine (BS 100–141, Estulic) were tested alone and in combination for their effects on… 
1982
1982
In the treatment of severe hypertension the choice of vasodilator is limited by side-effects, of which the lupus erythematosus… 
1982
1982
Three antihypertensive hydrazine derivatives (hydralazine, dihydralazine, and endralazine) were found to be genotoxic in four in… 
1982
1982
In a randomized cross-over trial in 23 patients with essential hypertension, a new peripheral vasodilator, endralazine, in a dose… 
1981
1981
1. The effects on blood pressure, heart rate and plasma renin activity of a new hydralazine congener, endralazine, were evaluated…